Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirs
Open Access
- 1 January 2011
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in HIV and AIDS
- Vol. 6 (1) , 80-85
Abstract
Purpose of review HIV-infected cells persisting in the face of highly active antiretroviral therapy are arguably the greatest hurdle to eradication of the virus from the body. Complementary strategies aimed at selective killing of infected cells are described. Recent findings Pioneered by research in the cancer field, various approaches are under development for selective killing of HIV-infected cells. These include targeted cytotoxic proteins, adoptive cell therapy, cytocidal virotherapy, and targeted nonbiological drug carriers. Summary These developmental efforts may provide a critical complement to antiretroviral therapy in efforts to achieve HIV eradication, or a ‘functional cure’ whereby therapy can be stopped without viral rebound.Keywords
This publication has 51 references indexed in Scilit:
- Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivoNature Biotechnology, 2010
- Adoptive T cell therapy of cancerCurrent Opinion in Immunology, 2010
- Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics☆Advanced Drug Delivery Reviews, 2009
- Adoptive transfer of virus-specific and tumor-specific T cell immunityCurrent Opinion in Immunology, 2009
- Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domainsProceedings of the National Academy of Sciences, 2009
- Radioimmunotherapy of Infectious DiseasesSeminars in Nuclear Medicine, 2009
- Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptorNature Medicine, 2008
- Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastomaNature Medicine, 2008
- Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleasesNature Biotechnology, 2008
- Use of antibodies and immunoconjugates for the therapy of more accessible cancersAdvanced Drug Delivery Reviews, 2008